Sustained Ca2+ burst signaling is crucial for endothelial vasodilator production and is disrupted by growth factors and cytokines. Conjugated linoleic acid (CLA), a Src inhibitor in certain preparations, is generally regarded as safe during pregnancy by the FDA. Multiple CLA preparations; t10, c12 or c9, t11 CLA, or a 1:1 mixture of the two were administered before growth factor or cytokine treatment. Growth factors and cytokines caused a significant decrease in Ca2+ burst numbers in response to ATP stimulation. Both t10, c12 CLA and the 1:1 mixture rescued VEGF165 or TNFα inhibited Ca2+ bursts and correlated with Src-specific phosphorylation of connexin 43. VEGF165, TNFα, and IL-6 in combination at physiologic concentrations revealed IL-6 amplified the inhibitory effects of lower dose of VEGF165 and TNFα. Again, the 1:1 CLA mixture was most effective at rescue of function. Therefore, CLA formulations may be a promising treatment for endothelial dysfunction in diseases such as preeclampsia.

中文翻译：

---

共轭亚油酸通过阻止生长因子和细胞因子介导的Cx43磷酸化来改善内皮细胞Ca2 +信号传导。

持续的Ca2 +爆发信号对于内皮血管扩张剂的产生至关重要，并且会被生长因子和细胞因子破坏。共轭亚油酸（CLA）是某些制剂中的Src抑制剂，通常被FDA认为在怀孕期间是安全的。多种CLA准备；在生长因子或细胞因子治疗之前，先施用t10，c12或c9，t11 CLA或两者的1：1混合物。生长因子和细胞因子导致对ATP刺激的Ca2 +爆发数量显着减少。t10，c12 CLA和1：1混合物均可挽救VEGF165或TNFα抑制的Ca2 +爆发，并与连接蛋白43的Src特异性磷酸化相关。在生理浓度下，VEGF165，TNFα和IL-6的组合显示IL-6增强了抑制作用。较低剂量的VEGF165和TNFα。同样，1：1种CLA混合物在恢复功能方面最有效。因此，CLA制剂可能是子痫前期等疾病中内皮功能障碍的有前途的治疗方法。